Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 1-3 , March 2008

Why is clinical progress in acute myelogenous leukemia so slow?

References 

  1. Appelbaum FR, Rowe JM, Radich J, et al. Acute myeloid leukemia. Hematology. American Society of Hematology. Education Program. 2001;62–86
  2. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clinic Proceedings. Mayo Clinic. 2006;81:247–260
  3. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. The New England Journal of Medicine. 1994;331:896–903
  4. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005;105:3420–3427
  5. Tubergen DC, Bleyer A. The leukemias. In:  Behrman RE,  Kliegman RM,  Jenson HB editor. Nelson textbook of pediatrics. Philadelphia: Saunders; 2003;p. 1694–1698

PII: S1521-6926(07)00092-8

doi: 10.1016/j.beha.2007.11.001

Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 1-3 , March 2008

Article Tools

* Image Usage & Resolution